Luts & Greenleigh Group’s AbbVie ABBV Stock Holding History

Luts & Greenleigh Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3M	Sell	13,796 -58	-0.4%	-$12.9K	2.38%	6
2025 Q4	$3.17M	Sell	13,854 -15	-0.1%	-$3.42K	2.69%	6
2025 Q3	$3.21M	Sell	13,869 -48	-0.3%	-$9.78K	2.88%	6
2025 Q2	$2.58M	Sell	13,917 -89	-0.6%	-$16.5K	2.48%	6
2025 Q1	$2.93M	Buy	14,006 +222	+2%	+$43.2K	2.92%	5
2024 Q4	$2.45M	Buy	13,784 +27	+0.2%	+$4.96K	2.42%	6
2024 Q3	$2.72M	Buy	13,757 +131	+1%	+$24.4K	2.61%	5
2024 Q2	$2.34M	Buy	+13,626	New	+$2.26M	2.43%	6
2023 Q4	$2.1M	Sell	13,554 -7	-0.1%	-$1.02K	2.65%	5
2023 Q3	$2.02M	Sell	13,561 -53	-0.4%	-$7.78K	2.51%	5
2023 Q2	$1.83M	Sell	13,614 -88	-0.6%	-$12.9K	2.26%	5
2023 Q1	$2.18M	Sell	13,702 -261	-2%	-$39.9K	2.77%	6
2022 Q4	$2.26M	Buy	+13,963	New	+$2.14M	2.86%	4

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Luts & Greenleigh Group's ABBV Position: Q1 2026 in Review

Luts & Greenleigh Group reduced its AbbVie (ABBV) stake by 0.42% in Q1 2026, selling an estimated $12.9K and leaving 13,796 shares worth $3M. The position accounts for 2.38% of the portfolio, ranked #6.

Luts & Greenleigh Group first reported a position in ABBV in Q4 2022 and has held it in 13 quarters since. The position peaked at $3.21M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Luts & Greenleigh Group held 13,796 shares of AbbVie worth $3M as of Q1 2026.
Luts & Greenleigh Group sold 58 AbbVie shares in Q1 2026, an estimated $12.9K.
AbbVie made up 2.38% of Luts & Greenleigh Group's portfolio in Q1 2026, its #6 holding.
Luts & Greenleigh Group first reported a position in AbbVie in Q4 2022 and has held it in 13 quarters since.
Luts & Greenleigh Group's AbbVie position peaked at $3.21M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Luts & Greenleigh Group's 13F filing for Q1 2026, filed 5 May 2026.